10x Genomics (TXG) Stock Analysis – Oversold Bounce, Strong Institutional Support, and LEAPS Setup

VIXTradingHub Analysis

📝 VIXTradingHub Analysis


🧠 TXG Stock Pick: 11-Criteria Deep Dive

Current price: $10.78 | Nov 2025 LEAPS 7.5 call ($4.10, Δ≈0.80)

1. 📉 RSI Oversold (≤30), Now Rebounding

2. 📈 MACD at Valley & Turning Up

  • No explicit MACD data found.

  • RSI surge and price stabilization suggest potential MACD recovery; needs chart confirmation.

3. 🏦 High Institutional Ownership + Recent Buying

4. 🧑‍💼 TXG Insider Buying in Recent Weeks

  • Mixed: CFO/CEO sold ~20K shares in May/Feb finance.yahoo.com.

  • Director Alan Mateo bought 40K shares at $11.14 in Feb ($446K) marketbeat.com.

  • ✅ Partial: some insider buying, but overshadowed by larger insider sells.

5. 📊 Analysts Raising Targets Recently

  • Consensus target ~$15.81 (~47% upside) fintel.io.

  • No confirmed recent target upgrades in past weeks—potentially unmet.

6. 🎯 Near-Term Catalysts Emerging

  • Last major event: Bruker settlement in May.

  • No new earnings or product launches within the next weeks highlighted.

7. 💡 Recession-Resilient & Emerging Tech

  • Operates in genomics tech—a durable & growing biotech framework.

  • Not fully recession-proof but part of emerging/business-critical tech.

8. 💵 Solid Fundamentals & Cash Flow

9. 📈 Options Flow: Calls > Puts OI & Volatility

10. 🔻 Recent Drop, Stabilizing, Plus Institutional Buy

  • Fell from $40s to $9–11; now stabilizing above $10 with bounce signs sec.gov+1marketbeat.com+1.

  • Institutional inflows support stability.

11. 🧨 Liquid LEAPS Calls (Nov ’25) vs. Puts

  • LEAPS exist (Nov 7.5 & 12.5 strikes); OI moderate sec.gov.

  • No clear call-heavy liquidity—watch for spread and execution issues.

✅ Scorecard: Criteria Met

# Criterion Met?
1 RSI bounce ✅
2 MACD recovery ⚠️
3 Institutional strong ✅
4 Insider buying ⚠️
5 Analyst upgrades ⚠️
6 Catalysts near-term ⚠️
7 Emerging tech ✅
8 Strong fundamentals ❌
9 Options call flow ❌
10 Bounce after drop ✅
11 LEAPS calls liquidity ⚠️

Total positive: 5 / 11 (+3 partials)

🧭 Final Analysis for TXG

Strengths: Current rebound from oversold levels, deep institutional interest, and a core position in emerging genomics tech make TXG appealing for a technically oriented swing or LEAPS trade.

Weaknesses: Weak profitability, absent insider appetite beyond one director, limited near-term catalysts, and tepid call-dominated options flow.

🧩 Recommendation

  • Active LEAPS traders: The Nov 2025 $7.50 call at ~$4.10 offers leveraged upside with ~30% buffer—but options liquidity is moderate, so beware bid-ask spreads.

  • Core equity holders: Consider scaling in modestly; ride the technical bounce while watching the next catalyst (e.g., Q2 earnings in July).

Learn more about LEAPS Strategy in our Stock Options Education Series.

⚠️ Capital Allocation Warning & Risk Management Advisory

Do not risk more than 2% of your total capital on this or any single trade.

Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:

  • 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.

  • 🛑 Use defined-risk setups and avoid emotional averaging down.

  • 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.

📜 Disclaimer

This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.

💰 5-Year Financial Overview for TXG

Metric20242023202220212020
Revenue610,785,000618,727,000516,409,000490,490,000298,845,000
Cost of Revenue196,303,000209,414,000120,386,00074,091,00058,468,000
Gross Profit414,482,000409,313,000396,023,000416,399,000240,377,000
Operating Expense609,041,000674,949,000563,967,000469,312,000325,701,000
Operating Income-194,559,000-194,949,000-167,944,000-52,913,000-85,324,000
Net Income-182,627,000-255,099,000-166,000,000-58,223,000-542,731,000
EPS (Diluted)-2-2-1-1-5
EBITDA-133,988,000-205,111,000-128,489,000-24,595,000-513,773,000
EBIT-----
Tax Provision4,927,0006,336,0004,029,0004,508,0008,255,000
Interest Income18,448,00016,906,0006,647,000206,0001,532,000
Interest Expense4,00033,000476,000866,0001,682,000
Total Expenses-----
Basic Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,687
Diluted Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,675

🧠 Analysis & Opinions on TXG

Loading widget...

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

📝 VIXTradingHub Analysis


🧠 TXG Stock Pick: 11-Criteria Deep Dive

Current price: $10.78 | Nov 2025 LEAPS 7.5 call ($4.10, Δ≈0.80)

1. 📉 RSI Oversold (≤30), Now Rebounding

2. 📈 MACD at Valley & Turning Up

  • No explicit MACD data found.

  • RSI surge and price stabilization suggest potential MACD recovery; needs chart confirmation.

3. 🏦 High Institutional Ownership + Recent Buying

4. 🧑‍💼 TXG Insider Buying in Recent Weeks

  • Mixed: CFO/CEO sold ~20K shares in May/Feb finance.yahoo.com.

  • Director Alan Mateo bought 40K shares at $11.14 in Feb ($446K) marketbeat.com.

  • ✅ Partial: some insider buying, but overshadowed by larger insider sells.

5. 📊 Analysts Raising Targets Recently

  • Consensus target ~$15.81 (~47% upside) fintel.io.

  • No confirmed recent target upgrades in past weeks—potentially unmet.

6. 🎯 Near-Term Catalysts Emerging

  • Last major event: Bruker settlement in May.

  • No new earnings or product launches within the next weeks highlighted.

7. 💡 Recession-Resilient & Emerging Tech

  • Operates in genomics tech—a durable & growing biotech framework.

  • Not fully recession-proof but part of emerging/business-critical tech.

8. 💵 Solid Fundamentals & Cash Flow

9. 📈 Options Flow: Calls > Puts OI & Volatility

10. 🔻 Recent Drop, Stabilizing, Plus Institutional Buy

  • Fell from $40s to $9–11; now stabilizing above $10 with bounce signs sec.gov+1marketbeat.com+1.

  • Institutional inflows support stability.

11. 🧨 Liquid LEAPS Calls (Nov ’25) vs. Puts

  • LEAPS exist (Nov 7.5 & 12.5 strikes); OI moderate sec.gov.

  • No clear call-heavy liquidity—watch for spread and execution issues.

✅ Scorecard: Criteria Met

# Criterion Met?
1 RSI bounce ✅
2 MACD recovery ⚠️
3 Institutional strong ✅
4 Insider buying ⚠️
5 Analyst upgrades ⚠️
6 Catalysts near-term ⚠️
7 Emerging tech ✅
8 Strong fundamentals ❌
9 Options call flow ❌
10 Bounce after drop ✅
11 LEAPS calls liquidity ⚠️

Total positive: 5 / 11 (+3 partials)

🧭 Final Analysis for TXG

Strengths: Current rebound from oversold levels, deep institutional interest, and a core position in emerging genomics tech make TXG appealing for a technically oriented swing or LEAPS trade.

Weaknesses: Weak profitability, absent insider appetite beyond one director, limited near-term catalysts, and tepid call-dominated options flow.

🧩 Recommendation

  • Active LEAPS traders: The Nov 2025 $7.50 call at ~$4.10 offers leveraged upside with ~30% buffer—but options liquidity is moderate, so beware bid-ask spreads.

  • Core equity holders: Consider scaling in modestly; ride the technical bounce while watching the next catalyst (e.g., Q2 earnings in July).

Learn more about LEAPS Strategy in our Stock Options Education Series.

⚠️ Capital Allocation Warning & Risk Management Advisory

Do not risk more than 2% of your total capital on this or any single trade.

Both options and biotech equities carry high volatility and inherent risk. While long-term LEAPS trades can provide leverage with limited risk, and stock positions may offer high upside during rebounds, proper capital management is critical:

  • 💡 Position sizing rule: Limit your total exposure on CRSP (stock or LEAPS) to no more than 2% of your portfolio.

  • 🛑 Use defined-risk setups and avoid emotional averaging down.

  • 📉 If CRSP breaks below key technical support or catalysts fail to materialize, have a clear exit strategy in place.

📜 Disclaimer

This content is for educational and informational purposes only and should not be considered financial advice or a recommendation to buy or sell any securities. Always conduct your own due diligence and consult with a licensed financial advisor before making investment decisions. Past performance is not indicative of future results. You are solely responsible for any investment decisions you make.

💰 5-Year Financial Overview for TXG

Metric20242023202220212020
Revenue610,785,000618,727,000516,409,000490,490,000298,845,000
Cost of Revenue196,303,000209,414,000120,386,00074,091,00058,468,000
Gross Profit414,482,000409,313,000396,023,000416,399,000240,377,000
Operating Expense609,041,000674,949,000563,967,000469,312,000325,701,000
Operating Income-194,559,000-194,949,000-167,944,000-52,913,000-85,324,000
Net Income-182,627,000-255,099,000-166,000,000-58,223,000-542,731,000
EPS (Diluted)-2-2-1-1-5
EBITDA-133,988,000-205,111,000-128,489,000-24,595,000-513,773,000
EBIT-----
Tax Provision4,927,0006,336,0004,029,0004,508,0008,255,000
Interest Income18,448,00016,906,0006,647,000206,0001,532,000
Interest Expense4,00033,000476,000866,0001,682,000
Total Expenses-----
Basic Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,687
Diluted Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,675

🧠 Analysis & Opinions on TXG

💰 5-Year Financial Overview for TXG

Metric20242023202220212020
Revenue610,785,000618,727,000516,409,000490,490,000298,845,000
Cost of Revenue196,303,000209,414,000120,386,00074,091,00058,468,000
Gross Profit414,482,000409,313,000396,023,000416,399,000240,377,000
Operating Expense609,041,000674,949,000563,967,000469,312,000325,701,000
Operating Income-194,559,000-194,949,000-167,944,000-52,913,000-85,324,000
Net Income-182,627,000-255,099,000-166,000,000-58,223,000-542,731,000
EPS (Diluted)-2-2-1-1-5
EBITDA-133,988,000-205,111,000-128,489,000-24,595,000-513,773,000
EBIT-----
Tax Provision4,927,0006,336,0004,029,0004,508,0008,255,000
Interest Income18,448,00016,906,0006,647,000206,0001,532,000
Interest Expense4,00033,000476,000866,0001,682,000
Total Expenses-----
Basic Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,687
Diluted Shares Outstanding120,451,550117,165,036113,858,684110,347,937101,151,675

🧠 Analysis & Opinions on TXG

📊 Technical Analysis Overview

Auto-loaded insights for today’s featured stock

Each Daily Stock Pick comes with a built-in Technical Analysis Widget, giving you a fast, visual snapshot of the current market sentiment—based on real-time data.

🔎 What You’ll See:

  • Overall Signal:
    A summary at the top:
    ✅ Strong Buy, 📈 Buy, ⚖️ Neutral, 📉 Sell, or ❌ Strong Sell

  • Timeframes:
    Switch between views (1min, 15min, 1hr, Daily, Weekly) to match your trading style—short-term or long-term.

  • Breakdown of Indicators:

    • Moving Averages – trend-following tools

    • Oscillators – momentum indicators like RSI & MACD

    • Pivots – support and resistance levels

💡 How to Use It:

This widget helps confirm or challenge your trading bias. Use it together with:

  • Our price targets

  • Options flow & volatility analysis

  • Institutional and insider sentiment

Options Chain

Select an expiration date to expand for table with strikes, greeks, and mark.

Join the Early Access List

“Get exclusive updates and launch bonuses.”

Scroll to Top